Top US court rejects Pfizer appeal and allows Nigerians to proceed with Trovan claims
This article was originally published in SRA
The US Supreme Court has declined to hear an appeal by Pfizer for review of a 2009 federal appeals court ruling that reinstated claims in US lawsuits by Nigerian families relating to the company's use of its antibiotic Trovan (trovafloxacin mesylate) in children during a meningitis epidemic1,2. The lawsuits claimed that the company, working in concert with Nigerian government officials, tested Trovan in children without obtaining informed consent, and failed to disclose the experimental nature of the study or the serious risks involved.
You may also be interested in...
ChemoCentryx has successfully completed its initial public offering on Nasdaq, raising $45 million to help support its multiple R&D programmes. It sold 4.5 million shares at $10, a somewhat less ambitious debut than it had originally planned in January when it wanted to sell four million shares at $14-$16. The reduced offer is a sign of the challenging nature of the IPO market, but ChemoCentryx's assessment of its own worth was at least closer to the market’s assessment that Cempra which got its IPO away on 6 February at valuation that was less than two-thirds of that implied by its initial prospectus (scripintelligence.com, 7 February 2012).
Ampio Pharmaceuticals, a development-stage company, initially raised $15 million which was boosted to $16.9 million by the exercise of overallotments by brokers. The shares were offered at $3.25, an 8.5% discount to the closing price of $3.66 on 12 July. The market pushed them down slightly further to 3.21 on 13 July.
Verastem, a cancer stem cells startup, has moved quickly to build its pipeline just five months after an initial public offering. Management at the Cambridge, Massachusetts firm believes that recent moves have accelerated Verastem's clinical development plans by a year.